Hugh Johnson Advisors LLC cut its holdings in Celgene Corporation (NASDAQ:CELG) by 2.3% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 21,821 shares of the biopharmaceutical company’s stock after selling 510 shares during the period. Hugh Johnson Advisors LLC’s holdings in Celgene Corporation were worth $2,715,000 at the end of the most recent quarter.
Other hedge funds have also added to or reduced their stakes in the company. Swiss National Bank grew its holdings in shares of Celgene Corporation by 27.2% in the first quarter. Swiss National Bank now owns 2,746,896 shares of the biopharmaceutical company’s stock valued at $341,796,000 after acquiring an additional 588,000 shares in the last quarter. Boston Partners grew its holdings in shares of Celgene Corporation by 0.3% in the first quarter. Boston Partners now owns 197,861 shares of the biopharmaceutical company’s stock valued at $24,620,000 after acquiring an additional 541 shares in the last quarter. Chicago Equity Partners LLC grew its holdings in shares of Celgene Corporation by 148.8% in the first quarter. Chicago Equity Partners LLC now owns 86,480 shares of the biopharmaceutical company’s stock valued at $10,761,000 after acquiring an additional 51,715 shares in the last quarter. Train Babcock Advisors LLC bought a new position in shares of Celgene Corporation in the first quarter valued at approximately $205,000. Finally, Personal Capital Advisors Corp grew its holdings in shares of Celgene Corporation by 11.3% in the first quarter. Personal Capital Advisors Corp now owns 233,811 shares of the biopharmaceutical company’s stock valued at $29,014,000 after acquiring an additional 23,686 shares in the last quarter. 79.43% of the stock is owned by institutional investors.
COPYRIGHT VIOLATION NOTICE: “Celgene Corporation (CELG) Shares Sold by Hugh Johnson Advisors LLC” was first posted by BBNS and is the sole property of of BBNS. If you are reading this report on another website, it was illegally stolen and reposted in violation of US & international copyright and trademark laws. The legal version of this report can be viewed at https://baseballnewssource.com/markets/celgene-corporation-celg-shares-sold-by-hugh-johnson-advisors-llc/1566121.html.
Several brokerages have weighed in on CELG. Oppenheimer Holdings, Inc. set a $148.00 price objective on Celgene Corporation and gave the company a “buy” rating in a report on Wednesday, June 14th. Cann reissued a “buy” rating on shares of Celgene Corporation in a report on Wednesday, June 7th. Canaccord Genuity set a $156.00 price objective on Celgene Corporation and gave the company a “buy” rating in a report on Tuesday, June 6th. Mizuho increased their price objective on Celgene Corporation from $130.00 to $134.00 and gave the company a “buy” rating in a report on Thursday, June 1st. Finally, BTIG Research reissued a “buy” rating and set a $138.00 price objective on shares of Celgene Corporation in a report on Wednesday, May 24th. One research analyst has rated the stock with a sell rating, seven have assigned a hold rating, twenty-one have given a buy rating and one has given a strong buy rating to the company. Celgene Corporation has an average rating of “Buy” and an average target price of $149.34.
Shares of Celgene Corporation (CELG) traded up 1.02% on Friday, hitting $142.04. The stock had a trading volume of 5,983,997 shares. The stock has a market cap of $111.12 billion, a PE ratio of 43.99 and a beta of 1.89. The company has a 50 day moving average price of $134.97 and a 200-day moving average price of $127.46. Celgene Corporation has a 12 month low of $96.93 and a 12 month high of $142.69.
Celgene Corporation (NASDAQ:CELG) last announced its earnings results on Thursday, July 27th. The biopharmaceutical company reported $1.82 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.61 by $0.21. The firm had revenue of $3.27 billion for the quarter, compared to analysts’ expectations of $3.23 billion. Celgene Corporation had a net margin of 21.35% and a return on equity of 68.51%. The business’s revenue was up 18.7% compared to the same quarter last year. During the same period in the prior year, the company earned $1.44 EPS. On average, equities research analysts anticipate that Celgene Corporation will post $7.33 earnings per share for the current year.
In other news, Director Michael D. Casey sold 9,250 shares of the company’s stock in a transaction dated Monday, June 19th. The shares were sold at an average price of $125.59, for a total transaction of $1,161,707.50. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Ernest Mario sold 18,506 shares of the company’s stock in a transaction dated Thursday, August 10th. The shares were sold at an average price of $130.52, for a total transaction of $2,415,403.12. Following the sale, the director now owns 69,424 shares in the company, valued at $9,061,220.48. The disclosure for this sale can be found here. Insiders have sold a total of 267,476 shares of company stock worth $35,812,841 over the last 90 days. Corporate insiders own 0.95% of the company’s stock.
Celgene Corporation Company Profile
Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.
Receive News & Ratings for Celgene Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene Corporation and related companies with our FREE daily email newsletter.